LUSV enhanced activity in combination with polychemotherapy. (A-C) A phase 2-like PDX study was performed using 9 PDX samples of patients with BCP-ALL and T-ALL with high CD127-expression levels (CD127hi). Mice were left untreated (control) or treated with LUSV, ALL induction-like chemotherapy (Chemo), or the combination (Combi). Chemotherapy comprised vincristine, dexamethasone, and PEG-asparaginase cycles as previously published.23,25,27 (A) Schematic depiction of the study setup. (B) Survival was analyzed using the Kaplan-Meier method and log-rank statistics. The P value was adjusted using the Bonferroni method, considering k = 6 comparisons. Hence, a P value of () = .0083 was considered at statistically significant. (C) The experiment was terminated after 260 days, and BM samples of sacrificed animals were analyzed for MRD by PCR for patient–specific Ig/T-cell receptor rearrangements. Overt ALL, mouse showed clinical signs of leukemia upon euthanasia. neg, negative (below detection limit); ns, not significant; n.r. = median survival not reached; PCR, polymerase chain reaction; Pos, MRD positivity (MRD level ≥10–3); neg, MRD negativity (MRD level <10–3).
